Analisis Cost-Consequences Terapi Penyakit Pneumonia Di Rumah Sakit Umum Daerah Praya, Nusa Tenggara Barat
DOI:
https://doi.org/10.46799/jhs.v3i4.470Keywords:
Cost consequence analysis;, Pneumonia;, Infection;, Antibiotic;Abstract
Pneumonia is an infection of lower respiratory tract caused by bacteria, viruses or fungi and a major cause of problem health in both developing and developed countries. Antibiotics are the first line therapy pneumonia caused by bacteria. Rational antibiotic therapy in the treatment of pneumonia is an important reason the need for pharmacoeconomic analysis. This study aimed to describe the cost of picture pneumonia treatment, the proportion of cost components, drug/drug combination that has the optimal effectiveness and the lowest cost. This research was descriptive non experimental research with retrospective data collection with method cost consequences analysis. Data taken were patient data with primary diagnoses of hospitalized pneumonia and according to inclusion and exclusion criteria. The results showed 57 patients met inclusion and exclusion criteria. Pneumonia patients are predominantly 0-18 years old (85.96%) and male sex with average treatment duration of 3 days. Proportion of drug costs (33.00%) with antibiotics (14.00%) and supportive/non antibiotic drugs (19.00%). The cost of treatment is the highest cost component of all cost components in the treatment of pneumonia. Cost of treatment of pneumonia disease without co-morbidities disease between Rp. 185.808 1.248.018. Cost of treatment of pneumonia with co-morbidities disease between Rp. 249.700-501.939. The most optimal antibiotic drug used in patients without co-morbidities disease is a combination of gentamicin-amoxicillin-ceftriaxone. The most optimal antibiotic drug is used in patients with co-morbidities that are combination of cefotaxim-ceftriaxon. The cost of treatment is the highest cost component of all cost components in the treatment of pneumonia and the most optimally used antibiotic is the combination of gentamicin-amoxicillin-ceftriaxon (patient without comorbidities) and a combination of cefotaxim-ceftriaxon (patients with comorbidities).
Published
Issue
Section
License
Copyright (c) 2022 Lila Wahyuni, Oktri Lestari, Elza Rachman Panca Priyanda, Riri Amanda Fitriani
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under aCreative Commons Attribution-ShareAlike 4.0 International (CC-BY-SA). that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
